Sign In  |  Register  |  About Walnut Creek Guide  |  Contact Us

Walnut Creek, CA
September 01, 2020 1:43pm
7-Day Forecast | Traffic

  • Search Hotels in Walnut Creek Guide

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Crispr Therapeutics Ag (NQ: CRSP )

64.54 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Dec 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 54,553
Open 64.54
Bid (Size) 62.60 (9)
Ask (Size) 62.90 (1)
Prev. Close 64.54
Today's Range 64.54 - 64.54
52wk Range 37.55 - 76.97
Shares Outstanding 78,935,098
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bull Of The Day: Crispr Therapeutics
CRISPR Therapeutics (CRSP) just made history on Friday with the first FDA-approved gene-editing medicine based on the Nobel Prize-winning discovery that targets disease with the billion-year old... 
Via Talk Markets
Is CRISPR Therapeutics a Good Stock to Buy Following Approval of Its First Drug?
A simultaneous pair of approvals from the U.S. Food and Drug Administration gives investors new factors to consider. 
Via The Motley Fool

Performance

YTD
+57.41%
+57.41%
1 Month
+21.41%
+21.41%
3 Month
+26.38%
+26.38%
6 Month
+7.75%
+7.75%
1 Year
+26.40%
+26.40%

More News

Read More
The 3 Best Cathie Wood Stocks to Buy in December
Via InvestorPlace
Vertex Pharmaceuticals Just Proved Something Big to Investors. Time to Buy?
Via The Motley Fool
FDA Approves First Gene-Editing Cell Therapy For Sickle Cell Disease, An Inherited Blood Disorder
Via Benzinga
Exposures Product Safety
Is This News a Setback or a Step Forward for CRISPR Therapeutics?
Via The Motley Fool
Here's How Much $1000 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today
Via Benzinga
The Latest Analyst Ratings for CRISPR Therapeutics
Via Benzinga
Stock Market Rally Nears 2023 Highs; AMD, Google Jump On AI Push: Weekly Review
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence Fossil Fuels
Vertex and CRISPR Therapeutics Announce US FDA Approval of CASGEVY™ (exagamglogene autotemcel) for the Treatment of Sickle Cell Disease
From Vertex Pharmaceuticals Incorporated
Via Business Wire
CRISPR Therapeutics Just Slashed Its Staff by 10%. Should Shareholders Be Worried?
Via The Motley Fool
Healthcare Gems: 3 Essential Long-Term Stock Picks
Via InvestorPlace
This Newly Discovered Risk Could Be a Big Headache for Vertex Pharmaceuticals and CRISPR Therapeutics
Via The Motley Fool
5 Unstoppable Trends to Invest $1,000 in for 2024
Via The Motley Fool
Next-Gen Biotech: 3 Companies Leading the Charge in Gene Therapy
Via InvestorPlace
CRISPR Therapeutics' Gene-Edited Oncology Pipeline To Focus On Expanded Use In Autoimmune Diseases
Via Benzinga
Better Growth Stock: CRISPR Therapeutics vs. Invitae
Via The Motley Fool
The Market's Up This Year. Do You Feel Like You Are Winning?
Via The Motley Fool
You Don't Have to Pick a Winner in Gene-Editing. Do This Instead.
Via The Motley Fool
Where Will Vertex Pharmaceuticals Be in 10 Years?
Via The Motley Fool
If You Invested $5,000 in CRISPR Therapeutics in January, This Is How Much You Would Have Today
Via The Motley Fool
Got $5,000? These Are 2 of the Best Growth Stocks to Buy Right Now
Via The Motley Fool
An Important History Lesson for Gene-Editing Investors
Via The Motley Fool
5 Top Stocks to Buy Before 2024
Via The Motley Fool
Five Best Performing Stocks Of The Top ETF Of November
Via Talk Markets
Topics ETFs
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 WalnutCreekGuide.com & California Media Partners, LLC. All rights reserved.